FindTrial
Sign In

Study of usage and outcomes of Polymyxin B in serious bacterial infection

Study of usage and outcomes of Polymyxin B for Systemic Bacterial Infections in Indian patients: A Registry Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/02/012183
Enrollment
50
Registered
2018-02-27
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Indian patients who are administered Polymyxin B for management of systemic bacterial infection as per routine clinical practice

Interventions

Intervention1: Nil: Nil Control Intervention1: Nil: Nil

Sponsors

Wockhardt Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: An Adult ( > 18 years) Indian patient of either gender who is reported to have received at least 1 dose of Polymyxin B for management of their systemic bacterial infection

Exclusion criteria

Exclusion criteria: Nil

Design outcomes

Primary

MeasureTime frame
1. Pattern of usage of Polymyxin B in various healthcare setups 2. Outcomes associated with therapy with Polymyxin B Timepoint: 1. At enrolment 2. At end of study—

Secondary

MeasureTime frame
1. Demographic and disease distribution of usage of Polymyxin B 2. Incidence of side effects and / or development of abnormal laboratory parameters 3. Cost Analysis of Polymyxin B therapy Timepoint: 1. At enrolment 2. Throughout polymyxin B treatment 3. Throughout polymyxin B treatment—

Countries

India

Contacts

Public ContactMr Ashish Mane

Wockhardt Limited

ashah@wockhardt.com02226596762

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026